Table 1 Patient characteristics and PET metabolic parameters in the training, internal validation and external validation cohort
|  | Training cohort (n = 117) | Internal Validation cohort (n = 50) | P values | External Validation cohort (n = 23) |
|---|---|---|---|---|
Age (years) | 53.93 ± 10.11 | 53.40 ± 9.90 | 0.753 | 50.65 ± 9.34 |
Age | Â | Â | 0.672 | Â |
 <55 years | 59 (50.43%) | 27 (54.00%) |  | 16 (69.56%) |
 ≥55 years | 58 (49.57%) | 23 (46.00%) |  | 7 (30.43%) |
Abortion | Â | Â | 0.426 | Â |
 No | 65 (55.56%) | 25 (50.00%) |  | 10 (43.48%) |
 Yes | 52 (44.44%) | 25 (50.00%) |  | 13 (56.52%) |
Menstruation status | Â | Â | 0.746 | Â |
 Premenopause | 46 (39.32%) | 21 (42.00%) |  | 14 (60.87%) |
 Menopause | 71 (60.68%) | 29 (58.00%) |  | 9 (39.13%) |
Pathology | Â | 0.997 | Â | |
 SCC | 110 (94.02%) | 47 (94.00%) |  | 19 (82.61%) |
 ADC | 7 (5.98%) | 3 (6.00%) |  | 4 (17.39%) |
FIGO stage | Â | Â | 0.169 | Â |
 IB3 | 5 (4.27%) | 1 (2.00%) |  | 0 (0%) |
 IIA - IIB | 18 (15.39%) | 8 (16.00%) |  | 8 (34.78%) |
 IIIA - IIIC | 90 (76.92%) | 35 (70.00%) |  | 11 (47.83%) |
 IVA | 4 (3.42%) | 6 (12.00%) |  | 4 (17.39%) |
MTD (cm) | Â | Â | 0.208 | Â |
 <4.25 | 37 (31.62%) | 11 (22.00%) |  | 9 (39.13%) |
 ≥4.25 | 80 (68.38%) | 39 (78.00%) |  | 14 (60.87%) |
LNM | Â | Â | 0.527 | Â |
 N 0 | 41 (35.04%) | 15 (30.00%) |  | 9 (39.13%) |
 N + | 76 (64.96%) | 35 (70.00%) |  | 14 (60.87%) |
EBRT total dose (Gy) | Â | Â | 0.890 | Â |
 <50.4 | 34 (29.06%) | 14 (28.00%) |  | 4 (17.39%) |
 ≥50.4 | 83 (70.94%) | 36 (72.00%) |  | 19 (82.61%) |
Chemotherapy regimen | Â | Â | 0.709 | Â |
 Cisplatin | 5 (4.27%) | 3 (6.00%) |  | 16 (69.56%) |
 Carboplatin | 65 (55.56%) | 30 (60.00%) |  | 1 (4.35%) |
 Nedaplatin | 47 (40.17%) | 17 (34.00%) |  | 6 (26.09%) |
Chemotherapy cycle | Â | Â | 0.673 | Â |
 3 | 39 (33.33%) | 15 (30.00%) |  | 1 (4.35%) |
 >3 | 78 (66.67%) | 35 (70.00%) |  | 22 (95.65%) |
LMR | Â | Â | 0.734 | Â |
 <3.25 | 43 (36.75%) | 17 (34.00%) |  | 5 (21.74%) |
 ≥3.25 | 74 (63.25%) | 33 (66.00%) |  | 18 (78.26%) |
NLR | Â | Â | 0.645 | Â |
 <3 | 70 (59.83%) | 28 (56.00%) |  | 22 (95.65%) |
 ≥3 | 47 (40.17%) | 22 (44.00%) |  | 1 (4.35%) |
PLR | Â | Â | 0.491 | Â |
 <150 | 38 (32.48%) | 19 (38.00%) |  | 16 (69.57%) |
 ≥150 | 79 (67.52%) | 31 (62.00%) |  | 7 (30.43%) |
MTV | 31.68 (15.10,52.36) | 35.65 (18.92,70.44) | 0.270 | 11.01 (6.56,26.34) |
TLG | 286.18 (130.08,576.00) | 330.40 (150.08,706.63) | 0.392 | 101.02 (57.04,180.98) |
SUVmax | 15.00 (11.69,21.36) | 14.37 (11.87,18.35) | 0.316 | 14.11 (9.75,17.54) |
SUVmean | 8.91 (6.91,12.08) | 8.39 (7.13,10.92) | 0.475 | 8.55 (5.54,11.00) |
SUVmin | 2.75 (2.32,3.44) | 2.59 (1.71,3.04) | 0.065 | 3.54 (2.60,4.53) |